G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 26.4 SEK 32% Market Closed
Market Cap: 1.7B SEK
Have any thoughts about
Genovis AB?
Write Note

Intrinsic Value

The intrinsic value of one GENO stock under the Base Case scenario is 23.95 SEK. Compared to the current market price of 26.4 SEK, Genovis AB is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GENO Intrinsic Value
23.95 SEK
Overvaluation 9%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Genovis AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GENO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GENO?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Genovis AB

Provide an overview of the primary business activities
of Genovis AB.

What unique competitive advantages
does Genovis AB hold over its rivals?

What risks and challenges
does Genovis AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genovis AB.

Provide P/S
for Genovis AB.

Provide P/E
for Genovis AB.

Provide P/OCF
for Genovis AB.

Provide P/FCFE
for Genovis AB.

Provide P/B
for Genovis AB.

Provide EV/S
for Genovis AB.

Provide EV/GP
for Genovis AB.

Provide EV/EBITDA
for Genovis AB.

Provide EV/EBIT
for Genovis AB.

Provide EV/OCF
for Genovis AB.

Provide EV/FCFF
for Genovis AB.

Provide EV/IC
for Genovis AB.

Show me price targets
for Genovis AB made by professional analysts.

What are the Revenue projections
for Genovis AB?

How accurate were the past Revenue estimates
for Genovis AB?

What are the Net Income projections
for Genovis AB?

How accurate were the past Net Income estimates
for Genovis AB?

What are the EPS projections
for Genovis AB?

How accurate were the past EPS estimates
for Genovis AB?

What are the EBIT projections
for Genovis AB?

How accurate were the past EBIT estimates
for Genovis AB?

Compare the revenue forecasts
for Genovis AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Genovis AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genovis AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genovis AB compared to its peers.

Compare the P/E ratios
of Genovis AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Genovis AB with its peers.

Analyze the financial leverage
of Genovis AB compared to its main competitors.

Show all profitability ratios
for Genovis AB.

Provide ROE
for Genovis AB.

Provide ROA
for Genovis AB.

Provide ROIC
for Genovis AB.

Provide ROCE
for Genovis AB.

Provide Gross Margin
for Genovis AB.

Provide Operating Margin
for Genovis AB.

Provide Net Margin
for Genovis AB.

Provide FCF Margin
for Genovis AB.

Show all solvency ratios
for Genovis AB.

Provide D/E Ratio
for Genovis AB.

Provide D/A Ratio
for Genovis AB.

Provide Interest Coverage Ratio
for Genovis AB.

Provide Altman Z-Score Ratio
for Genovis AB.

Provide Quick Ratio
for Genovis AB.

Provide Current Ratio
for Genovis AB.

Provide Cash Ratio
for Genovis AB.

What is the historical Revenue growth
over the last 5 years for Genovis AB?

What is the historical Net Income growth
over the last 5 years for Genovis AB?

What is the current Free Cash Flow
of Genovis AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Genovis AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Genovis AB

Current Assets 180m
Cash & Short-Term Investments 135.8m
Other Current Assets 44.2m
Non-Current Assets 123.4m
Long-Term Investments 90k
PP&E 91.4m
Intangibles 19.4m
Other Non-Current Assets 12.5m
Current Liabilities 18.8m
Other Current Liabilities 18.8m
Non-Current Liabilities 77m
Long-Term Debt 75.1m
Other Non-Current Liabilities 2m
Efficiency

Earnings Waterfall
Genovis AB

Revenue
127m SEK
Cost of Revenue
-45.2m SEK
Gross Profit
81.8m SEK
Operating Expenses
-58.6m SEK
Operating Income
23.2m SEK
Other Expenses
-5.9m SEK
Net Income
17.3m SEK

Free Cash Flow Analysis
Genovis AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GENO Profitability Score
Profitability Due Diligence

Genovis AB's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
Positive 3-Year Average ROE
70/100
Profitability
Score

Genovis AB's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

GENO Solvency Score
Solvency Due Diligence

Genovis AB's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
79/100
Solvency
Score

Genovis AB's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GENO Price Targets Summary
Genovis AB

Wall Street analysts forecast GENO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GENO is 38.76 SEK with a low forecast of 28.28 SEK and a high forecast of 54.6 SEK.

Lowest
Price Target
28.28 SEK
7% Upside
Average
Price Target
38.76 SEK
47% Upside
Highest
Price Target
54.6 SEK
107% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GENO?

Click here to dive deeper.

Dividends

Genovis AB
does not pay dividends
Shareholder Yield

Current shareholder yield for GENO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Genovis AB

Country

Sweden

Industry

Life Sciences Tools & Services

Market Cap

1.7B SEK

Dividend Yield

0%

Description

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Contact

SKANE
Lund
Medicon Village, Scheelevagen 2
+4646101230.0
www.genovis.com

IPO

2005-11-11

Employees

33

Officers

President & CEO
Mr. Fredrik Olsson
Group Chief Financial Officer
Mr. Magnus Langberg
Vice President of Sales & Marketing
Ms. Rikke Rytter
Controller
Ms. Maria Edholm
President of Genovis Inc.
Mr. John M. Lindsay B.A., BA

See Also

Discover More
What is the Intrinsic Value of one GENO stock?

The intrinsic value of one GENO stock under the Base Case scenario is 23.95 SEK.

Is GENO stock undervalued or overvalued?

Compared to the current market price of 26.4 SEK, Genovis AB is Overvalued by 9%.

Back to Top